Maryland is currently home to 2679 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Baltimore, Bethesda, Rockville and Annapolis. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Fetoscopic Endoluminal Tracheal Occlusion (FETO) for Severe Left Diaphragmatic Hernia (CDH)
NCT02710968
Recruiting
Despite advances in prenatal diagnosis and postnatal therapies, including extracorporeal membrane oxygenation (ECMO), inhaled nitric oxide therapy, and ventilator strategies that minimize ventilator-induced lung injury, morbidity and mortality rates for babies with congenital diaphragmatic hernia (CDH) remain high. The survival relates to the degree of prenatal lung compression and the subsequent impairment of pulmonary function following delivery. Prenatal assessment by ultrasound or magnetic r... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/04/2024
Locations: Johns Hopkins Center for Fetal Therapy, Baltimore, Maryland
Conditions: Congenital Diaphragmatic Hernia
Register for Updates
Detection and Characterization of Neurologic Manifestations of Inborn and Acquired Errors of Immunity
NCT06169150
Recruiting
Background: Immune system and nervous system have significant interaction so that People with immunity diseases can have complications that affect the nervous system and people with some neurological disease may have defects in their immune system.These complications can affect many body functions, including how they move, walk, think, and feel. Researchers do not fully understand how immune diseases affect the nervous system. By learning more, they hope to create more effective treatments. Ob... Read More
Gender:
ALL
Ages:
Between 2 years and 120 years
Trial Updated:
10/03/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Nervous System Disease, Immune System Disease
Register for Updates
Comparing Use of Incentive Spirometry with and Without Reminder
NCT06101030
Recruiting
This study is designed to determine if patients using an incentive spirometer with visual and auditory signals will increase their use of the incentive spirometer and prevent lung complications.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/03/2024
Locations: Tidal Reseach Site, Silver Spring, Maryland
Conditions: Post Operative
Register for Updates
A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia
NCT05926765
Recruiting
This study will assess the efficacy and safety of bilateral intra-parotid administration of AAV2-hAQP1 in adults with Grade 2 or Grade 3 radiation-induced late xerostomia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/03/2024
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands
Register for Updates
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
NCT05150691
Recruiting
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/02/2024
Locations: Holy Cross Hospital, Silver Spring, Maryland
Conditions: HER2-positive Advanced Solid Tumor
Register for Updates
Personalized Treatment in Thyroid Disorders
NCT03517579
Recruiting
The Collar Therapy Indicator (CoTI) (A device that is placed in collar around the neck resembling a turtle neck sweater collar with a wire and recording box) has been shown in a single small previously published experience to provide data regarding radioiodine exposure that correlates with conventional methods of measuring I-123 and I-131 uptakes after diagnostic dose administration and/or therapy for thyroid disorders. We hypothesize that the device's continuous measurement capability will perm... Read More
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
10/02/2024
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Thyroid Cancer, Graves Disease
Register for Updates
2321GCCC: CRD3874-SI in Patients with Relapsed/refractory AML
NCT06626633
Recruiting
This clinical research study is being done to answer questions about how to treat cancer. To clear cancer cells from the body, the immune system needs the action of proteins called Type 1 interferons. The protein STING (for STimulator of INterferon Genes) stimulates the body to make Type 1 interferons. Type 1 interferons activate key molecules in cancer immunity to kill cancer cells. CRD3874 is a synthetic drug that activates STING, and STING stimulates the immune system to kill cancer cells.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/01/2024
Locations: University of Maryland, Baltimore, Baltimore, Maryland
Conditions: Acute Myeloid Leukemia
Register for Updates
Study to Assess AFM24 in Combination with Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers
NCT05109442
Recruiting
AFM24-102 is a Phase 1/2a open-label, non-randomized, multicenter, dose escalation, and expansion study evaluating AFM24 in combination with atezolizumab in patients with selected EGRF-expressing advanced solid malignancies whose disease has progressed after treatment with previous anticancer therapies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/01/2024
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Advanced Solid Tumor
Register for Updates
Vaporized Cannabis Administration and Co-Administration of Alcohol on Impairment
NCT06293040
Recruiting
This human laboratory study will use cognitive, behavioral, and subjective measures to characterize impairment associated with co-use of alcohol and vaporized cannabis. Participants (n=32) will complete 7 double-blind, double-dummy outpatient sessions in randomized order. In each session, participants will self-administer placebo (0 mg THC) or active vaporized cannabis (5 or 25 mg THC, via a handheld vaporizer called the Mighty Medic) and a placebo drink (BAC 0.0%) or alcohol drink calculated to... Read More
Gender:
ALL
Ages:
21 years and above
Trial Updated:
09/30/2024
Locations: Johns Hopkins Behavioral Pharmacology Research Unit, Baltimore, Maryland
Conditions: Cannabis Intoxication, Alcohol Intoxication
Register for Updates
Effectiveness of Dry Needling in Linear Scar Tissue
NCT06033430
Recruiting
Scar tissue can cause serious complications that significantly impact a patient's quality of life. Common complications include stiffness and contractions, which can restrict joint mobility and make daily activities challenging. In severe cases, these limitations can even prevent patients from fulfilling their work responsibilities or engaging in activities they enjoy. The deleterious effect of scar tissue on a patient's well-being is of utmost significance. However, several therapeutic approach... Read More
Gender:
ALL
Ages:
Between 20 years and 60 years
Trial Updated:
09/30/2024
Locations: Myopain Seminars, Bethesda, Maryland
Conditions: Scar Tissue, Hypertrophic Scar, Hypertrophic Scar of Upper Arm (Disorder), Hypertrophic Surgical Scar, Dry Needling
Register for Updates
Global Blood-Brain Barrier Disruption and Post-Stroke Cognitive Decline
NCT05556395
Recruiting
The goal of this study is to gain a better understanding of why some individuals who have suffered a stroke experience post-stroke cognitive decline. Specifically this study is testing whether global disruption of the blood-brain barrier detected at the time of the stroke is informative about the risk of post-stroke cognitive decline over the next 3 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/26/2024
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Ischemic Stroke
Register for Updates
Olorofim Aspergillus Infection Study
NCT05101187
Recruiting
The purpose of this study is to compare treatment with olorofim versus treatment with AmBisome® followed by standard of care (SOC) in patients with IFD caused by proven IA or probable lower respiratory tract disease Aspergillus species (invasive aspergillosis, IA).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/26/2024
Locations: The Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Invasive Aspergillosis
Register for Updates